Biotron files SARS therapeutic patent
Tuesday, 29 July, 2003
Researchers at Biotron have filed a patent covering the blocking of specific ion channel activity formed within the E protein of the SARS virus, offering a potentially new treatment for the disease.
SARS, a coronavirus respiratory syndrome with a death rate of almost 10 per cent, has proved particularly difficult to treat as the lung damage resulting from the viral infection is often sufficiently severe that it leads to adult respiratory distress disorder (ARDD), which can often demand external breathing assistance to keep the patient alive.
Biotron claimed to be the first to report that the coronavirus E protein forms an ion channel, and indicated that it would be investigating the use of ion channel targeting to inhibit viral replication and thus stop the spread of the virus.
The company's technology, dubbed Virion, has previously been targeted on HIV-1 and hepatitis C viruses, but the new findings will mean an extension of the existing platform to cover SARS.
The news boosted the company's share price (ASX: BIT) to AUD$0.42 at press time.
Stem cell experiments conducted in space
Scientists are one step closer to manufacturing stem cells in space — which could speed up...
Plug-and-play test evaluates T cell immunotherapy effectiveness
The plug-and-play test enables real-time monitoring of T cells that have been engineered to fight...
Common heart medicine may be causing depression
Beta blockers are unlikely to be needed for heart attack patients who have a normal pumping...
